MaxCyte, Inc. (MXCT) income statement
MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3062% below fair value
$1.19+0.00 (0.00%)
Close on Nov 13, 2026Market cap $122.82MP/E –Yield –
MaxCyte, Inc. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, TTM
- Gross margin
- 81.0%
- Operating margin
- -98.0%
- Net margin
- -81.4%
- Return on equity, FY2025
- -23.6%
Financial strength
- Current ratio
- 7.83
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 84.0%
Valuation
- P/E ratio
- –
- Price to sales
- 3.57
- Price to book
- 0.81
- Dividend yield
- –
See a number that looks wrong?